{"entity":{"id":"idea-reg-academic-cart-at-cost-coverage","kind":"idea","name":"Public payers cover academic CAR-T at cost as a benchmark for commercial prices","aka":[],"tldr":"Hospitals in Spain make their own CAR-T for a third of the commercial price. Paying for such products at cost gives health systems a lever in negotiating with companies.","summary":"ARI-0001 and similar academic products are reimbursed in Spain under the hospital exemption at a fraction of commercial list prices, and published outcomes are comparable in matched populations. The proposal is for other public payers to establish explicit coverage of academic point-of-care CAR-T at audited cost plus a fixed margin, publish that cost, and use it as the reference price in negotiations for commercial products in the same indication, creating a competitive benchmark that does not otherwise exist for single-source therapies.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)","url":"https://doi.org/10.1038/nrclinonc.2017.31"}],"tags":[],"related":["idea-reg-point-of-care-cart-network"],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-manufacturing-cell-therapy"],"keyPapers":["paper-prasad-nat-rev-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Payers that cover academic CAR-T at cost negotiate commercial CAR-T prices at least 25% lower than payers without an academic alternative within three years, and treat more patients per unit spend.","rationale":"Monopoly pricing persists where there is no alternative; a credible, reimbursed public-sector alternative is the fastest way to create one for cell therapies, since biosimilar-style competition does not yet exist.","test":"Compare commercial CAR-T net prices and patient volumes between Spain and comparable European countries; replicate by establishing academic coverage in one further country and remeasuring after three years.","maturity":"early-clinical","actor":"payer","cost":"medium","horizonYears":3},"route":"/ideas/idea-reg-academic-cart-at-cost-coverage/","neighbours":{"idea":[{"id":"idea-reg-point-of-care-cart-network","kind":"idea","name":"Hospital-made CAR-T under one shared regulatory master file","route":"/ideas/idea-reg-point-of-care-cart-network/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"paper":[{"id":"paper-prasad-nat-rev-clin-oncol","kind":"paper","name":"The high price of anticancer drugs: origins, implications, barriers, solutions","route":"/key-papers/paper-prasad-nat-rev-clin-oncol/"}]}}